Press Release / Media Release
Please find enclosed press release for the financial results for the quarter and half year ended September 30, 2017. Please take the above on record.10-11-2017
Press Release / Media Release
Please find enclosed press release for the financial results for the quarter and half year ended September 30, 2017. Please take the above on record.Unaudited Financial Results For The Quarter Ended September 30, 2017.
Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the unaudited financial results for the quarter and half year ended September 30, 2017, which were approved by the Board of Directors of the Company at its Meeting held today, that commenced at 11:30 a.m. and concluded at 1:45 p.m....No dearth of suitors for consumer health business, says Pfizer
Pfizer said the supply challenges would have a negative impact of "several hundred million dollars" this year, moderating in 2018Board Meeting For The Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2017 And Intimation Of Closure Of Trading Window.
This is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, November 10, 2017, inter alia, to consider and take on record the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2017. Please be informed that the Trading Window for trading in the Equity shares of the Company will be closed from October 31, 2017 to November 12, 2017, both days inclusive.Health ministry can invoke provision of Patent Act to reduce cost of procurement of Prevnar 13 under UIP: says Dr Nair
Even though the Indian patent office has granted Pfizer a patent for Prevnar 13 pneumonia vaccine making it unaffordable for many, the Union health ministry can invoke government use provision under sectionPneumonia vaccine case traces the fine line on public health
The legal battle that brews over Pfizer's pneumococcal vaccine in India is set to create a benchmark of sorts for vaccines in the arena of public health. Until now, innovation, access and...Pfizer to start auction process for its consumer healthcare unit in Nov
The prospective sale was first mooted on Oct 10, when Pfizer said it was considering strategic options for the unitHow UCLA is fighting proxy patent battle for expensive cancer drug in India
UCLA appears to be representing the pharma firms Pfizer, Medivation and Astellas in its battle. They aren't telling the Delhi high court about thisPanaceaBiotec, MSFIndia oppose Pfizer's pneumonia vaccine patent
Panacea Biotec files a review petition with the patent office seeking revocation of the patent given to Pfizer; MSF India moves Delhi high court to overturn patentCompany news
Pfizer plans strategic alternatives for its consumer healthcare business, including full or partial separation of the segment through a spin-off, sale or other transaction, the company said in a...